Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.

@article{Heery2017PhaseIS,
  title={Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.},
  author={Christopher R. Heery and Claudia M Palena and Sheri McMahon and Renee Nicole Donahue and Lauren M. Lepone and Italia Grenga and Ulrike Dirmeier and Lisa M. Cordes and Jenn Mart{\'e} and William L. Dahut and Harpreet Singh and Ravi Amrit Madan and Romaine Ingrid Fernando and Duane Howard Hamilton and Jeffrey Schlom and James L. Gulley},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2017},
  volume={23 22},
  pages={
          6833-6845
        }
}
Purpose: The transcription factor brachyury has been shown in preclinical studies to be a driver of the epithelial-to-mesenchymal transition (EMT) and resistance to therapy of human tumor cells. This study describes the characterization of a Modified Vaccinia Ankara (MVA) vector-based vaccine expressing the transgenes for brachyury and three human costimulatory molecules (B7.1, ICAM-1, and LFA-3, designated TRICOM) and a phase I study with this vaccine.Experimental Design: Human dendritic cells… CONTINUE READING
BETA

Similar Papers

Loading similar papers…